Predictors of cardiac toxicity: univariate analysis
| Characteristics . | Adults, n (%) N = 585 . | HR . | 95% CI . | P . |
|---|---|---|---|---|
| Age, y Age >55 Age ≤55 | 309 (53) 276 (47) | 2.3 1.0 | 1.1-4.5 | .02 |
| Disease status Active Remission | 356 61) 229 (39) | 2.1 1.0 | 1.0-4.5 | .05 |
| GVHD prophylaxis PTCy-based Non-PTCy | 272 (46) 313 (53) | 1.3 1.0 | 0.7-2.4 | .4 |
| Preparative regimen Reduced intensity Myeloablative | 201 (34) 384 (66) | 0.9 1.0 | 0.5-1.9 | .9 |
| Stem cell source Peripheral blood Bone marrow | 475 (81) 110 (19) | 0.9 1.0 | 0.4-1.9 | .7 |
| History of anthracycline Yes No | 335 (57) 250 (43) | 0.9 1.0 | 0.5-1.7 | .8 |
| History of HTN Yes No | 235 (40) 350 (60) | 2.3 1.0 | 1.2-4.5 | .01 |
| History of hyperlipidemia Yes No | 115 (20) 470 (80) | 1.5 1.0 | 0.7-2.9 | .3 |
| Smoker Yes No | 227 (39) 356 (61) | 1.6 | 0.8-3.0 | .1 |
| Karnofsky Performance Scale <90 ≥90 | 230 (39) 287 (49) | 0.7 1.0 | 0.4-1.4 | .3 |
| Specific HCT-CI comorbidity | ||||
| Cardiac* Yes No | 54 (9) 531 (91) | 3.6 1.0 | 1.8-7.1 | <.001 |
| Arrhythmia† Yes No | 39 (7) 546 (93) | 3.5 1.0 | 1.5-7.9 | .003 |
| Heart valve‡ Yes No | 11 (2) 574 (98) | Not evaluable | — | .4 |
| Diabetes Yes No | 63 (11) 522 (89) | 2.3 — | 1.1-5 | .04 |
| Pulmonary 0 2 3 | 335 (57) 190 (33) 60 (10) | 1.0 1.2 0.8 | 0.6-2.3 0.2-2.6 | .6 .7 |
| Obesity Yes No | 76 (13) 509 (87) | 1.8 1.0 | 0.8-3.9 | .1 |
| Characteristics . | Adults, n (%) N = 585 . | HR . | 95% CI . | P . |
|---|---|---|---|---|
| Age, y Age >55 Age ≤55 | 309 (53) 276 (47) | 2.3 1.0 | 1.1-4.5 | .02 |
| Disease status Active Remission | 356 61) 229 (39) | 2.1 1.0 | 1.0-4.5 | .05 |
| GVHD prophylaxis PTCy-based Non-PTCy | 272 (46) 313 (53) | 1.3 1.0 | 0.7-2.4 | .4 |
| Preparative regimen Reduced intensity Myeloablative | 201 (34) 384 (66) | 0.9 1.0 | 0.5-1.9 | .9 |
| Stem cell source Peripheral blood Bone marrow | 475 (81) 110 (19) | 0.9 1.0 | 0.4-1.9 | .7 |
| History of anthracycline Yes No | 335 (57) 250 (43) | 0.9 1.0 | 0.5-1.7 | .8 |
| History of HTN Yes No | 235 (40) 350 (60) | 2.3 1.0 | 1.2-4.5 | .01 |
| History of hyperlipidemia Yes No | 115 (20) 470 (80) | 1.5 1.0 | 0.7-2.9 | .3 |
| Smoker Yes No | 227 (39) 356 (61) | 1.6 | 0.8-3.0 | .1 |
| Karnofsky Performance Scale <90 ≥90 | 230 (39) 287 (49) | 0.7 1.0 | 0.4-1.4 | .3 |
| Specific HCT-CI comorbidity | ||||
| Cardiac* Yes No | 54 (9) 531 (91) | 3.6 1.0 | 1.8-7.1 | <.001 |
| Arrhythmia† Yes No | 39 (7) 546 (93) | 3.5 1.0 | 1.5-7.9 | .003 |
| Heart valve‡ Yes No | 11 (2) 574 (98) | Not evaluable | — | .4 |
| Diabetes Yes No | 63 (11) 522 (89) | 2.3 — | 1.1-5 | .04 |
| Pulmonary 0 2 3 | 335 (57) 190 (33) 60 (10) | 1.0 1.2 0.8 | 0.6-2.3 0.2-2.6 | .6 .7 |
| Obesity Yes No | 76 (13) 509 (87) | 1.8 1.0 | 0.8-3.9 | .1 |
Cardiac includes coronary artery disease (≥1 vessel coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart failure, myocardial infarction, and ejection fraction ≤50%.
Arrhythmia is defined as atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias.
Heart valve is any heart valve disease except mitral valve prolapse.